ClinicalTrials.gg
TerminatedNCT00695396Updated Oct 5, 2012Results posted

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

A Phase 3 interventional study of Placebo and Epoetin alfa in Myelodysplastic Syndromes and Anemia, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-05.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was stopped due to low subject enrollment. No safety issue or other concern factored into this decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes — 2 open to participants now, 4 under way, 2 of them phase 3. Epoetin Alfa · Myelodysplastic Syndromes.

Started
2008
with 1 other
Phase 3
5 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes, this one is one of 2 that started in 2008, is one of 5 in phase 3, and was the 5th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

2 of the 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate that Epoetin alfa treatment reduces red blood cell transfusions in anemic patients with myelodysplastic syndromes (MDS). Myelodysplastic syndromes are a group of disorders characterized by progressive bone marrow failure and an increased risk of development of leukemia.

Read the detailed description

This is a randomized (patients are assigned by chance to a treatment group), double-blind (neither the patient or the physician know which treatment is being received by the patient), placebo-controlled, multicenter study of epoetin alfa in anemic patients who are diagnosed with myelodysplastic syndromes (MDS) according to protocol-specified criteria. Patients meeting entry criteria for the study will be randomly assigned to receive epoetin alfa 40,000 IU or 80,000 IU or a matching volume of placebo administered by subcutaneous (under the skin) injection once every week. Doses of study drug will be withheld, decreased, or increased on the basis of weekly hemoglobin concentrations monitored in patients and predefined dose adjustment guidelines. An Independent Data Monitoring Committee (IDMC) will periodically review study data and for the assessment of disease progression, an independent central reviewer will review bone marrow specimens and peripheral blood counts. Safety will be monitored throughout the study at predetermined intervals and as clinically indicated by physical examination, laboratory tests and evaluation of adverse events. Patients in the Treatment Phase will be randomly assigned to receive once weekly epoetin alfa subcutaneously (SC) at a dose of 40,000 IU (1 mL) or 80,000 IU (2ML) or matching volume of placebo (1 mL or 2 mL) once every week for 48 weeks. Patients may continue to receive double-blinded treatment after 48-weeks.

03

Conditions studied

  • Myelodysplastic Syndromes
  • Anemia

Keywords

  • MDS
  • Myelodysplastic syndromes
  • Anemia
  • Epoetin alfa
  • EPO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MDS according to protocol-specified criteria via bone marrow studies performed within 12 weeks before randomization

Exclusion criteria

Exclusion Criteria:

  • No prior or concurrent treatment with epoetin alfa or any other approved or experimental erythropoietin stimulating agents (ESAs) within the previous 12 months before randomization
  • No prior use of approved or experimental agents for the treatment of MDS or recent treatment with granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) for the treatment of neutropenia
  • Patients must not have secondary MDS or anemia caused by factors other than MDS (including iron deficiency, vitamin B12 or folate deficiencies, hemolysis, chronic renal failure, or gastrointestinal bleeding)
  • No history (within 12 months) of deep venous thrombosis
  • or history (within 6 months) of stroke, acute coronary syndrome or other arterial thrombosis
  • Not currently receiving therapeutic anticoagulants or have uncontrolled hypertension
  • No uncontrolled disease or dysfunction deemed by the Investigator not attributable to MDS
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    001

    Epoetin alfa 40 000 IU subcutaneously once every week (1 mL dose) for 48 weeks

    Drug: Epoetin alfa

  • Experimental
    002

    Epoetin alfa 80 000 IU subcutaneously once every week (2 mL dose) for 48 weeks

    Drug: Epoetin alfa

  • Placebo comparator
    003

    Placebo Matching volume 1 mL for 48 weeks

    Drug: Placebo

  • Placebo comparator
    004

    Placebo Matching volume 2 mLfor 48 weeks

    Drug: Placebo

Interventions

  • DrugPlacebo

    Matching volume 2 mLfor 48 weeks

  • 40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks

  • DrugPlacebo

    Matching volume 1 mL for 48 weeks

  • 80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks

06

What researchers measure

Primary outcomes

  1. Red Blood Cell (RBC) Transfusion

    Incidence of participants who received at least 1 Red Blood Cell (RBC) transfusion during the study (from randomization through the end of study)

    Time frame: Approximately 48 weeks

Secondary outcomes

  1. RBC Transfusion From Day 29 Through the End of Study

    incidence of participants who received at least 1 RBC transfusion from Day 29 through the end of study (approximately 48 weeks).

    Time frame: Day 29 through the end of study (approximately 48 weeks)

  2. Transfusion Dependent

    Participants who were transfusion-dependent were those who received 4 or more RBC units during a consecutive 8-week period.

    Time frame: Approximately 48 weeks

07

Results

Posted Mar 17, 2011
Limitations and caveats
Because this study was terminated prematurely due to slow enrollment, only limited data were collected. No formal statistical testing was performed. Only descriptive statistics were provided.

Participant flow

Participant flow — Overall Study
MilestonePlaceboEpoetin Alfa 40000 IUEpoetin Alfa 80000 IU
Started889
Completed101
Not completed788
Withdrew: Study closed prematurely568
Withdrew: Withdrawal by subject220

Outcome measures

PrimaryRed Blood Cell (RBC) Transfusion

Incidence of participants who received at least 1 Red Blood Cell (RBC) transfusion during the study (from randomization through the end of study)

Time frame:
Approximately 48 weeks
Reported as:
Number · participants
Red Blood Cell (RBC) Transfusion
participantsPlaceboEpoetin Alfa 40000 IUEpoetin Alfa 80000 IU
Red Blood Cell (RBC) Transfusion531
SecondaryRBC Transfusion From Day 29 Through the End of Study

incidence of participants who received at least 1 RBC transfusion from Day 29 through the end of study (approximately 48 weeks).

Time frame:
Day 29 through the end of study (approximately 48 weeks)
Reported as:
Number · participants
RBC Transfusion From Day 29 Through the End of Study
participantsPlaceboEpoetin Alfa 40000 IUEpoetin Alfa 80000 IU
RBC Transfusion From Day 29 Through the End of Study421
SecondaryTransfusion Dependent

Participants who were transfusion-dependent were those who received 4 or more RBC units during a consecutive 8-week period.

Time frame:
Approximately 48 weeks
Reported as:
Number · participants
Transfusion Dependent
participantsPlaceboEpoetin Alfa 40000 IUEpoetin Alfa 80000 IU
Transfusion Dependent221

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/8 (25%)7/8 (87.5%)
Epoetin Alfa 40000 IU—2/8 (25%)4/8 (50%)
Epoetin Alfa 80000 IU—4/9 (44.4%)6/9 (66.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboEpoetin Alfa 40000 IUEpoetin Alfa 80000 IU
Aplasia Pure Red CellBlood and lymphatic system disorders1/80/80/9
Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/80/80/9
Vision BlurredEye disorders0/81/80/9
Gastrointestinal HaemorrhageGastrointestinal disorders0/81/80/9
AstheniaGeneral disorders0/81/80/9
HyperhidrosisSkin and subcutaneous tissue disorders0/81/80/9
AnaemiaBlood and lymphatic system disorders0/80/81/9
SplenomegalyBlood and lymphatic system disorders0/80/81/9
Humerus FractureInjury, poisoning and procedural complications0/80/81/9
Wrist FractureInjury, poisoning and procedural complications0/80/81/9
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPlaceboEpoetin Alfa 40000 IUEpoetin Alfa 80000 IU
FatigueGeneral disorders2/82/81/9
AnaemiaBlood and lymphatic system disorders2/80/80/9
DizzinessNervous system disorders2/80/81/9
DyspnoeaRespiratory, thoracic and mediastinal disorders2/81/81/9
Upper Respiratory Tract InfectionInfections and infestations0/82/81/9
NauseaGastrointestinal disorders0/81/82/9
AstheniaGeneral disorders1/80/82/9
Abdominal DiscomfortGastrointestinal disorders1/80/80/9
DiarrhoeaGastrointestinal disorders1/81/80/9
HaematocheziaGastrointestinal disorders1/80/80/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboEpoetin Alfa 40000 IUEpoetin Alfa 80000 IUTotal
<=18 years0000
Between 18 and 65 years1124
>=65 years77721
Age Continuous
Age Continuous(years)PlaceboEpoetin Alfa 40000 IUEpoetin Alfa 80000 IUTotal
Mean73 ± 10.5277.3 ± 9.7867.7 ± 9.8972.4 ± 10.44
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEpoetin Alfa 40000 IUEpoetin Alfa 80000 IUTotal
Female23712
Male65213
Region of Enrollment
Region of Enrollment(participants)PlaceboEpoetin Alfa 40000 IUEpoetin Alfa 80000 IUTotal
CANADA1001
ITALY0101
RUSSIA2046
USA57517
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2008
First posted
Jun 11, 2008
Start
Jun 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Mar 17, 2011
Last update
Oct 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00695396
First posted
Jun 11, 2008
Start date
Jun 2008
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Mar 17, 2011
Last update
Oct 5, 2012

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion